- Home
- CGAU vs UPB Comparison
CGAU vs UPB Comparison
Compare CGAU & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- UPB
- Stock Information
- Founded
- CGAU 2002
- UPB 2021
- Country
- CGAU Canada
- UPB United States
- Employees
- CGAU N/A
- UPB N/A
- Industry
- CGAU Precious Metals
- UPB
- Sector
- CGAU Basic Materials
- UPB
- Exchange
- CGAU Nasdaq
- UPB NYSE
- Market Cap
- CGAU 1.2B
- UPB 1.1B
- IPO Year
- CGAU N/A
- UPB 2024
- Fundamental
- Price
- CGAU $5.85
- UPB $17.99
- Analyst Decision
- CGAU Buy
- UPB Strong Buy
- Analyst Count
- CGAU 3
- UPB 4
- Target Price
- CGAU $11.00
- UPB $56.50
- AVG Volume (30 Days)
- CGAU 852.3K
- UPB 280.8K
- Earning Date
- CGAU 10-31-2024
- UPB 02-14-2025
- Dividend Yield
- CGAU 3.56%
- UPB N/A
- EPS Growth
- CGAU N/A
- UPB N/A
- EPS
- CGAU 0.47
- UPB N/A
- Revenue
- CGAU $1,252,073,000.00
- UPB $2,207,000.00
- Revenue This Year
- CGAU $16.18
- UPB N/A
- Revenue Next Year
- CGAU N/A
- UPB N/A
- P/E Ratio
- CGAU $11.84
- UPB N/A
- Revenue Growth
- CGAU 29.99
- UPB 82.10
- 52 Week Low
- CGAU $4.47
- UPB $15.92
- 52 Week High
- CGAU $7.82
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- CGAU 42.01
- UPB N/A
- Support Level
- CGAU $5.72
- UPB N/A
- Resistance Level
- CGAU $6.06
- UPB N/A
- Average True Range (ATR)
- CGAU 0.17
- UPB 0.00
- MACD
- CGAU 0.02
- UPB 0.00
- Stochastic Oscillator
- CGAU 28.30
- UPB 0.00
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets worldwide. The company manages its reportable operating segments by a combination of geographic location and products. The Kyrgyz Republic segment includes the operations of the Kumtor Gold Project. The Turkish segment represents the development of the OksUt Project. The North America Gold- Copper segment represents the operations of the Mount Milligan Mine. The North America Molybdenum segment includes the operations of the Langeloth processing facility and the care and maintenance activities of the Endako and Thompson Creek Mines.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.